Prostatype Genomics AB (PROGEN) — Strategic Asset Allocation Index
Prostatype Genomics AB (PROGEN) has a Strategic Asset Allocation Index of 0.0% as of December 2022. Strategic assets (PP&E of Skr3.60K plus long-term investments of Skr-) total Skr3.60K, measured against net assets of Skr26.15 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Prostatype Genomics AB Strategic Asset Allocation Index (2016–2022)
This chart shows how Prostatype Genomics AB's Strategic Asset Allocation Index has evolved across 6 annual periods from 2016 to 2022. As of December 2022, the index stands at 0.0%, representing strategic assets of Skr3.60K against net assets of Skr26.15 Million SEK. Explore Prostatype Genomics AB (PROGEN) cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Prostatype Genomics AB (2016–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Prostatype Genomics AB from 2016 to 2022, covering 6 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see PROGEN stock market capitalisation.
| Year | SAAI | Strategic Assets (SEK) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 0.0% | Skr3.60K | Skr3.60K | Skr- | Skr26.15 Million | ▼ 0.0 pp |
| 2021 | 0.0% | Skr14.09K | Skr14.09K | Skr- | Skr35.91 Million | ▼ -0.1 pp |
| 2020 | 0.1% | Skr28.22K | Skr28.22K | Skr- | Skr28.29 Million | ▼ -0.4 pp |
| 2018 | 0.5% | Skr39.55K | Skr39.55K | Skr- | Skr8.55 Million | ▼ -1.0 pp |
| 2017 | 1.5% | Skr92.35K | Skr92.35K | Skr- | Skr6.22 Million | ▲ +0.1 pp |
| 2016 | 1.4% | Skr212.57K | Skr212.57K | Skr- | Skr14.93 Million | — |